MICRORNA BIOMARKERS FOR CERVICAL CANCER

宫颈癌的 MICRORNA 生物标志物

• 批准号: 8827726
• 负责人: Xiaowei Wang
• 金额: $ 16.58万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-01 至 2017-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8827726
• 关键词: American Cancer Society; Biological Assay; Biological Markers; Cancer Patient; Cancer Prognosis; Cervix Neoplasms; Cervix Uteri; Cessation of life; Clinic; Clinical; Code; Computer Simulation; Data; Development; Disease; Early identification; Experimental Models; Family; Genes; Goals; Human; Machine Learning; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Methods; MicroRNAs; Modeling; Molecular Profiling; Outcome; Pathologic; Patients; Performance; Play; Prognostic Marker; Proteins; Radiation therapy; Research; Role; Sampling; Staging; Testing; Time; Treatment Failure; Tumor-Associated Process; United States; Untranslated RNA; Validation; Weight; Woman; base; cancer diagnosis; cancer therapy; cancer type; chemotherapy; high risk; improved; individualized medicine; miRNA expression profiling; outcome forecast; predictive modeling; prognostic; prognostic value; public health relevance; therapy outcome; treatment planning; tumor; tumorigenesis

DESCRIPTION (provided by applicant): Project Summary It is estimated that there will be about 12,340 new cases of cervical cancer and those 4,030 women will die of this disease this year in the United States (American Cancer Society). Worldwide, invasive cervical cancer is an even greater problem and is the second most commonly diagnosed cancer in women. A method to accurately predict cervical cancer outcome prior to standard therapy would be critical for the early identification of patients with high risk of treatment failures. For these high-risk patients modified therapy could potentially be applied for improved patient survival. However, traditional clinic pathologic features, such as tumor grade and stage, have limited prognostic values in cervical cancer. Thus, new methods need to be developed for improved prognostic performance. In this proposed research, we will test the hypothesis that the expression signature of multiple selected microRNAs can reliably predict the outcome of cervical cancer. MicroRNAs (miRNAs) are a newly discovered family of small non- coding RNA molecules that collectively control the expression of thousands of protein-coding genes. Recent studies indicate that miRNAs are promising biomarkers to predict cancer therapy outcomes. However, the prognostic value of miRNAs in cervical cancer has not been investigated. The major goal of this research is to build a miRNA-based model to robustly predict cervical cancer outcome. Our preliminary analysis has identified two miRNAs that are predictive of cervical cancer outcome. Here, we propose to significantly expand our preliminary study to identify new miRNA biomarkers by analyzing all cervix-related miRNAs in a large number of cervical tumors. These miRNA biomarkers will then be combined to build a robust model for significantly improved prognosis of cervical cancer.

据估计，今年美国将有大约12，340例宫颈癌新发病例，其中4，030名妇女将死于这种疾病（美国癌症协会）。在世界范围内，浸润性宫颈癌是一个更大的问题，是第二个最常见的女性癌症诊断。在标准治疗之前准确预测宫颈癌结局的方法对于早期识别具有治疗失败高风险的患者至关重要。对于这些高危患者，改良治疗可能会提高患者的生存率。然而，传统的临床病理特征，例如肿瘤分级和分期，对宫颈癌的预后价值有限。因此，需要开发新的方法来改善预后。在这项拟议的研究中，我们将测试多个选定的microRNA的表达特征可以可靠地预测宫颈癌的结果的假设。microRNA（miRNAs）是新近发现的一类非编码RNA小分子，它们共同控制着数千个蛋白质编码基因的表达。最近的研究表明，miRNA是预测癌症治疗结果的有希望的生物标志物。然而，miRNAs在宫颈癌中的预后价值尚未研究。这项研究的主要目标是建立一个基于miRNA的模型来预测宫颈癌的结果。我们的初步分析已经确定了两种预测宫颈癌结局的miRNAs。在这里，我们建议通过分析大量宫颈肿瘤中所有宫颈相关的miRNA来显著扩展我们的初步研究，以识别新的miRNA生物标志物。然后将这些miRNA生物标志物结合起来，建立一个强大的模型，以显着改善宫颈癌的预后。